These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 23798472)

  • 1. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA; Wilfong AA; Holland-Bouley K; Anderson AE; Agricola K; Tudor C; Mays M; Lopez CM; Kim MO; Franz DN
    Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
    Krueger DA; Wilfong AA; Mays M; Talley CM; Agricola K; Tudor C; Capal J; Holland-Bouley K; Franz DN
    Neurology; 2016 Dec; 87(23):2408-2415. PubMed ID: 27815402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
    Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
    Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clobazam therapy of refractory epilepsy in tuberous sclerosis complex.
    Jennesson M; van Eeghen AM; Caruso PA; Paolini JL; Thiele EA
    Epilepsy Res; 2013 May; 104(3):269-74. PubMed ID: 23219029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epileptic spasms in tuberous sclerosis complex.
    Hsieh DT; Jennesson MM; Thiele EA
    Epilepsy Res; 2013 Sep; 106(1-2):200-10. PubMed ID: 23796861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
    Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
    Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery.
    Elliott RE; Carlson C; Kalhorn SP; Moshel YA; Weiner HL; Devinsky O; Doyle WK
    Epilepsy Behav; 2009 Nov; 16(3):454-60. PubMed ID: 19767244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epilepsy in TSC: certain etiology does not mean certain prognosis.
    Vignoli A; La Briola F; Turner K; Scornavacca G; Chiesa V; Zambrelli E; Piazzini A; Savini MN; Alfano RM; Canevini MP
    Epilepsia; 2013 Dec; 54(12):2134-42. PubMed ID: 24304436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus alters white matter diffusion in tuberous sclerosis complex.
    Tillema JM; Leach JL; Krueger DA; Franz DN
    Neurology; 2012 Feb; 78(8):526-31. PubMed ID: 22262746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study.
    Stockinger J; Strzelczyk A; Nemecek A; Cicanic M; Bösebeck F; Brandt C; Hamer H; Intravooth T; Steinhoff BJ
    Epilepsia; 2021 Mar; 62(3):785-794. PubMed ID: 33534134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
    Overwater IE; Rietman AB; Bindels-de Heus K; Looman CW; Rizopoulos D; Sibindi TM; Cherian PJ; Jansen FE; Moll HA; Elgersma Y; de Wit MC
    Neurology; 2016 Sep; 87(10):1011-8. PubMed ID: 27511181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
    Curatolo P; Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; de Vries PJ; Dlugos DJ; Fan J; Ridolfi A; Pelov D; Voi M; French JA
    Lancet Child Adolesc Health; 2018 Jul; 2(7):495-504. PubMed ID: 30169322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
    Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis].
    Zou L; Liu Y; Pang L; Ju J; Shi Z; Zhang J; Chen X; Su X; Hu L; Shi X; Yang X
    Zhonghua Er Ke Za Zhi; 2014 Nov; 52(11):812-6. PubMed ID: 25582464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.